These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 15303252

  • 1. Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.
    Thiemermann C.
    Br J Pharmacol; 2004 Jul; 142(6):1049-51. PubMed ID: 15303252
    [Abstract] [Full Text] [Related]

  • 2. Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.
    Thiemermann C.
    Br J Pharmacol; 2004 Jan; 141(1):1-3. PubMed ID: 14662733
    [Abstract] [Full Text] [Related]

  • 3. Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury.
    Cuzzocrea S.
    Vascul Pharmacol; 2004 Jul; 41(6):187-95. PubMed ID: 15653094
    [Abstract] [Full Text] [Related]

  • 4. Peroxisome proliferator-activated receptors and acute lung injury.
    Cuzzocrea S.
    Curr Opin Pharmacol; 2006 Jun; 6(3):263-70. PubMed ID: 16580256
    [Abstract] [Full Text] [Related]

  • 5. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH, Roufogalis BD.
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [Abstract] [Full Text] [Related]

  • 6. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB.
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [Abstract] [Full Text] [Related]

  • 7. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.
    Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, Thiemermann C.
    FASEB J; 2002 Jul; 16(9):1027-40. PubMed ID: 12087064
    [Abstract] [Full Text] [Related]

  • 8. Diverse cardioprotective signaling mechanisms of peroxisome proliferator-activated receptor-gamma ligands, 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone, in reperfusion injury: role of nuclear factor-kappaB, heat shock factor 1, and Akt.
    Zingarelli B, Hake PW, Mangeshkar P, O'Connor M, Burroughs TJ, Piraino G, Denenberg A, Wong HR.
    Shock; 2007 Nov; 28(5):554-63. PubMed ID: 17589386
    [Abstract] [Full Text] [Related]

  • 9. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM, Schiffrin EL.
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [Abstract] [Full Text] [Related]

  • 10. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.
    Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Di Paola R, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C.
    Br J Pharmacol; 2003 Sep; 140(2):366-76. PubMed ID: 12970094
    [Abstract] [Full Text] [Related]

  • 11. PPAR-gamma: therapeutic target for ischemic stroke.
    Culman J, Zhao Y, Gohlke P, Herdegen T.
    Trends Pharmacol Sci; 2007 May; 28(5):244-9. PubMed ID: 17416424
    [Abstract] [Full Text] [Related]

  • 12. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.
    Setti G, Hayward A, Dessapt C, Barone F, Buckingham R, White K, Bilous R, Hiroshi K, Gruden G, Viberti G, Gnudi L.
    Am J Nephrol; 2010 May; 32(5):393-402. PubMed ID: 20814199
    [Abstract] [Full Text] [Related]

  • 13. Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cells: thiazolidinediones are partial PPAR gamma agonists.
    Chana RS, Lewington AJ, Brunskill NJ.
    Kidney Int; 2004 Jun; 65(6):2081-90. PubMed ID: 15149321
    [Abstract] [Full Text] [Related]

  • 14. Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.
    Vázquez M, Silvestre JS, Prous JR.
    Methods Find Exp Clin Pharmacol; 2002 Oct; 24(8):515-23. PubMed ID: 12500431
    [Abstract] [Full Text] [Related]

  • 15. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
    Hidalgo-Figueroa S, Ramírez-Espinosa JJ, Estrada-Soto S, Almanza-Pérez JC, Román-Ramos R, Alarcón-Aguilar FJ, Hernández-Rosado JV, Moreno-Díaz H, Díaz-Coutiño D, Navarrete-Vázquez G.
    Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
    [Abstract] [Full Text] [Related]

  • 16. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP.
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [Abstract] [Full Text] [Related]

  • 17. A new insight into the treatment of diabetes by means of pan PPAR agonists.
    Chandra A, Kaur P, Sahu SK, Mittal A.
    Chem Biol Drug Des; 2022 Dec; 100(6):947-967. PubMed ID: 34990085
    [Abstract] [Full Text] [Related]

  • 18. Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist.
    Agrawal R, Jain P, Dikshit SN.
    Mini Rev Med Chem; 2012 Feb; 12(2):87-97. PubMed ID: 22372600
    [Abstract] [Full Text] [Related]

  • 19. Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction.
    Tao L, Wang Y, Gao E, Zhang H, Yuan Y, Lau WB, Chan L, Koch WJ, Ma XL.
    Circ Res; 2010 Feb 05; 106(2):409-17. PubMed ID: 19940263
    [Abstract] [Full Text] [Related]

  • 20. Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.
    Sauer S.
    Trends Pharmacol Sci; 2015 Oct 05; 36(10):688-704. PubMed ID: 26435213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.